The pharmaceutical company Pfizer boasted impressive results of observations that show that the medicine for home use against coronavirus is also effective against the Omicron strain. These pills reduce the risk of death or hospitalization due to COVID-19 by 89%.
Pharmaceutical giant Pfizer has stated that its unique tablets for home use against coronavirus also work against the Omicron strain. Laboratory tests suggested that this twice-daily drug called paklovid still provides a fairly powerful reaction against the most recent variant of the coronavirus. The company also announced the latest clinical data on its drug, which show that it reduces the risk of vulnerable adults being hospitalized due to coronavirus or dying because of it by 90%.
The results are taken from studies involving 2,200 adults from risk groups. They coincide with the initial observations of Pfizer, according to which this drug was recognized by clinicians as “capable of changing the rules of the game” in the fight against coronavirus. Manufacturers of another antiviral pill, molnupiravir, which is the only one approved in the UK for outpatient treatment of covid, were forced to reconsider the effectiveness of this drug, as there were concerns that the results of initial clinical trials were too optimistic.
Molnupiravir, which is produced by American companies Merck and Ridgeback, will be given only to elderly people from risk groups within 48 hours after infection with the virus, and pilot studies are expected to be launched in the coming days. In separate studies of Pfizer’s paklovid, healthy unvaccinated adults were also involved, in whom this drug reduces the risk of severe disease by 70% if taken a few days after a positive PCR test.